Key facts
- It has raised $1.1M; the latest was Later Stage VC ($1.0M) in May 2025.
- Notable investors include Johnson & Johnson Innovation - JLABS, Althea Group (New York), California Institute for Regenerative Medicine, Canadian Institutes of Health Research, CureDuchenne Ventures — 9 tracked in total.
- Entos Pharmaceuticals has filed 1 Form D with the SEC, most recently May 2020 ($100K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Entos Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Entos Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Entos Pharmaceuticals
Developer of a nucleic acid-based therapy designed to treat cancer. The company's therapy uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells effectively to extra-hepatic targets, and the technology applies to a wide range of therapeutic types, including gene therapy, enabling health organizations to treat cancer effectively.
- Sector
- Healthcare
- HQ
- Edmonton, Canada
- Founded
- 2016
- Employees
- 50
- Website
- entospharma.com/
- Ownership
- Privately Held (backing)
Entos Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Entos Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Entos Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.